Fusion to Acquire Ipsen's IPN-1087 to Expand its Pipeline of Radiopharmaceuticals
Shots:
- Ipsen to receive 400-000 shares at closing and an additional 200-000 shares as milestones- $81.63M as development and regulatory milestones & $423.24M as commercial milestones along with royalties on net sales
- Fusion will be responsible for paying to a third-party licensor up to $84.7M in development milestones and royalties on net sales of products
- IPN-1087 is a small molecule targeting NTSR1. Fusion plans to use IPN-1087 to create an alpha-emitting radiopharmaceutical- FPI-2059- targeting solid tumors expressing NTSR1
Ref: PRNewswire | Image: Fusion Pharma
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
